Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: Techniques are disclosed related to determining delay in a radio frequency (RF) communications device configured to perform envelope tracking. The RF communications device may comprise a power amplifier and an envelope tracker. First and second input stimuli signals may be transmitted to each of the power amplifier and envelope tracker, respectively. The RF communications device may output, by the power amplifier, an output signal to a vector signal analyzer (VSA). The VSA may determine a first delay offset by cross-correlating the output signal with a reference signal, and the VSA may determine a second delay offset based on an amplitude distortion of the output signal. A relative delay between the first and second input stimuli signals may be determined based on a difference between the first and second delay offsets.

Abstract: The present invention relates to a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer, comprising the measurement of the amounts of specific isoforms of GATA6 and/or NKX2-1 in a sample of said subject. Furthermore, the present invention relates to a composition for use in medicine comprising (an) inhibitor(s) of specific isoforms of GATA6 and/or NKX2-1. Additionally, the present invention relates to a kit for use in a method of assessing whether a subject suffers from cancer or is prone to suffering from cancer, in particular lung cancer.

Abstract: The present invention relates to hair treatment agents containing selected fatty acid amides and selected protein hydrolysates.

Abstract: The present invention relates to hair treatment compositions comprising a synergistic combination of selected fatty acid amides and further selected fragrances.

Abstract: Hair treatment compositions include a synergistic combination of fragrances and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines.

Abstract: Compositions for treating keratinic fibers, in particular human hair, which in addition to the conditioning properties and the gloss and tactile properties of keratinic fibers, in particular human hair, exhibit an improved action over prior art compositions with regard to the removal of dandruff from the keratinic fibers.

Abstract: The invention generally relates to metabolic labeling of a target organism with a stable isotope. In a first aspect, the present invention relates to a method for metabolic labeling of a target organism with a stable isotope. The present invention also relates to a method of producing a diet for metabolic labeling of a target organism and to a diet composition for metabolic labeling of a target organism. In a further aspect the invention describes the use of the diet composition according to the present invention for producing a metabolically labeled target organism as a reference for a quantitative proteomic approach. The present invention also relates, in a further aspect, to the use of a diet composition for pulse SILAC labeling. The present invention also relates to the use of a target organism labeled by the method according to the first aspect of the present invention as a spike-in standard in quantitative proteomics approaches.

Abstract: Hair preparations containing selected cationic silicones and dimethicone are used for the treatment of keratin fibers, in particular human hair.

Abstract: The invention relates to hair preparations containing selected cationic silicones and at least one B series vitamin as well as to the use of said preparations for the treatment of keratin fibers, in particular human hair.